Author
Dana-Farber Cancer InstituteORCID 0000-0001-7213-3951Unclaimed ORCID profile · follow to get notified of new preprints
5 papers
Recent·Most cited
Richard Y. Ebright, Yao He, Alan G. Zhang…·William R. Sellers
The paper identifies combinatorial KRAS/FGFR dependence in pancreatic cancer through genetic interaction mapping and shows that combined inhibition overcomes resistance.
Pornlada Likasitwatanakul, Zhixin Li, Khoa Tat Doan…·Nilay S. Sethi
The paper identifies HDAC1/2 inhibition as a method to promote colorectal cancer differentiation through H3K27ac gains, which can be reversed by blocking EP300.
Vindhya Vijay, Negin Karisani, Lei Shi…·Nabeel M. Bardeesy
This study creates a biliary tract cancer cell line atlas using multi-omics data to identify molecular subtypes and therapeutic targets.
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton…·Kenneth P. Olive
This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.
D. Gulhan, Vinay Viswanadham, Francesc Muyas…·Peter J. Park
The paper identifies mutational signatures SBS26 and SBS54 in MMRD tumors that correlate with immune checkpoint blockade response and survival, suggesting their use as prognostic biomarkers.